Protalix Biotherapeutics (PLX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,562 | -6,798 | -4,595 | 8,312 | 14,356 |
| Depreciation Amortization | 970 | 641 | 322 | 1,458 | 1,086 |
| Income taxes - deferred | 236 | -207 | -138 | -3,092 | -3,092 |
| Accounts receivable | 3,069 | -5,308 | 1,746 | -428 | -4,188 |
| Other Working Capital | 4,258 | 5,932 | 8,084 | -10,589 | -18,313 |
| Other Operating Activity | -288 | 6,318 | -1,231 | 3,021 | 5,238 |
| Operating Cash Flow | $4,683 | $578 | $4,188 | $-1,318 | $-4,913 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 20,420 | N/A | N/A | 5,000 | 5,000 |
| PPE Investments | -854 | -770 | -598 | -1,149 | -899 |
| Purchase Of Investment | N/A | N/A | N/A | -20,420 | -20,420 |
| Other Investing Activity | -25 | -16 | -8 | -142 | -50 |
| Investing Cash Flow | $19,541 | $-786 | $-606 | $-16,711 | $-16,369 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -20,420 | N/A | N/A | N/A | N/A |
| Common Stock Issued | N/A | N/A | N/A | 24,666 | 24,666 |
| Financing Cash Flow | $-20,420 | $N/A | $N/A | $24,666 | $24,666 |
| Exchange Rate Effect | -29 | -27 | -7 | -114 | -87 |
| Beginning Cash Position | 23,634 | 23,634 | 23,634 | 17,111 | 17,111 |
| End Cash Position | 27,409 | 23,399 | 27,209 | 23,634 | 20,408 |
| Net Cash Flow | $3,775 | $-235 | $3,575 | $6,523 | $3,297 |
| Free Cash Flow | |||||
| Operating Cash Flow | 4,683 | 578 | 4,188 | -1,318 | -4,913 |
| Capital Expenditure | -857 | -770 | -598 | -1,149 | -899 |
| Free Cash Flow | 3,826 | -192 | 3,590 | -2,467 | -5,812 |